Improving lopinavir genotype algorithm through phenotype correlations: Novel mutation patterns and amprenavir cross-resistance

AIDS

Volumn 17, Issue 7, 2003, Pages 955-961

  Parkin, Neil T ^a,b   Chappey, Colombe ^a   Petropoulos, Christos J ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b NONE   (United States)

Author keywords

Amprenavir; Genotype; HIV; Lopinavir; Phenotype; Protease; Resistance

Indexed keywords

AMPRENAVIR; LOPINAVIR; PROTEINASE INHIBITOR;

ALGORITHM; ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IC 50; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; VIRUS MUTATION;

ALGORITHMS; CARBAMATES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PHENOTYPE; PYRIMIDINONES; SULFONAMIDES;

EID: 0038555736     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00003     Document Type: Article

References (24)

1. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
2. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998, 42:2775-2783.
3. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002, 185:599-607.
4. Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother 2002, 3:315-327.
5. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen C-M, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998, 42:3218-3224.
6. Carrillo A, Stewart KD, Sham HL, Norbeck DW, Kohlbrenner WE, Leonard JM, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998, 72:7532-7541.
7. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001, 75:7462-7469.
8. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002, 7:165-174.
9. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, et al. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 2002, 46:731-738.
10. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
11. Hellmann N, Johnson P, Petropoulos C. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSenseHIV. Antivir Ther 1999, 4(suppl 1):34.
12. Parikh U, Hammond J, Calef C, Larder B, Schinazi R, Mellors JW. Mutations in retroviral genes associated with drug resistance. http://hiv-web.lanl.gov/content/hiv-db/COMPENDIUM/2000/partl/Mell ors.pdf. 2001; Accessed April 2002.
13. Erickson J, Gulnik S, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999, 13:S189-S204.
14. Race E, Dam E, Obry V, Paulous S, Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999, 13:2061-2068.
15. Schapiro JM, Winters MA, Lawrence J, Merigan TC. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. AIDS 1999, 13:359-365.
16. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Vlair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995, 39:1704-1710.
17. Parkin NT, Chappey C, Maranta M, Whitehurst N, Petropoulos CJ. Genotypic and phenotypic analysis of a large database of patient samples reveals distinct patterns of protease inhibitor cross-resistance. Antivir Ther 2001, 6(suppl 1):49.
18. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 2002, 16:1009-1017.
19. Haubrich R, Keiser P, Kemper C and the CCTG Study Team. CCTG 575: a randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy. Antivir Ther 2001, 6(suppl 1):63.
20. Katzenstein D, Bosch RJ, Wang N, Hellmann NS, Bacheler L, Albrecht M, et al. Baseline phenotypic susceptibility and virologic failure over 144 weeks among nucleoside RT inhibitor experienced subjects in ACTG 364. In 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 591-T].
21. Parkin N, Paxinos E, Chappey C, Wrin MT, Gamarnik A, Petropoulos C. Genetic correlates of increased susceptibility to protease inhibitors in wild type viruses. Antivir Ther 2002, 7(suppl 1):S72.
22. Isaacson J, Kempf D, Calvez V, Cohen-Codar I, Descamps D, Guillevic E, et al. Quantitative estimate of the effect of individual baseline mutations in HIV protease on the virologic response to lopinavir/ritonavir therapy in heavily antiretroviral-experienced patients. In 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 {abstract 559-T].
23. Loutfy M, Thompson C, Trpeski M, Kovacs C, Rachlis A, Goodhew J, et al. Influence of genotypic resistance on the viral load response of 167 patients on lopinavir/r (LPV/r) including an analysis of new protease inhibitor resistant mutations in 21 patients who failed. In 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [poster 560-T].
24. Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, et al. Human Immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002, 46:2926-2932.